28,877 Shares in Merit Medical Systems, Inc. $MMSI Purchased by Van Hulzen Asset Management LLC

Van Hulzen Asset Management LLC acquired a new position in Merit Medical Systems, Inc. (NASDAQ:MMSI) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 28,877 shares of the medical instruments supplier’s stock, valued at approximately $2,002,000.

A number of other institutional investors have also recently bought and sold shares of the business. Kilter Group LLC acquired a new position in shares of Merit Medical Systems during the 2nd quarter worth approximately $25,000. Los Angeles Capital Management LLC acquired a new stake in shares of Merit Medical Systems in the fourth quarter valued at approximately $25,000. Torren Management LLC bought a new stake in shares of Merit Medical Systems in the fourth quarter valued at approximately $38,000. Covestor Ltd boosted its stake in shares of Merit Medical Systems by 252.6% in the fourth quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier’s stock valued at $41,000 after buying an additional 336 shares during the period. Finally, Danske Bank A S acquired a new stake in Merit Medical Systems during the third quarter worth approximately $42,000. Institutional investors own 99.66% of the company’s stock.

Wall Street Analysts Forecast Growth

MMSI has been the topic of a number of recent research reports. Bank of America raised their price objective on Merit Medical Systems from $92.00 to $97.00 and gave the stock a “neutral” rating in a research note on Thursday, August 13th. Canaccord Genuity Group increased their target price on Merit Medical Systems from $85.00 to $94.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Robert W. Baird set a $98.00 price target on Merit Medical Systems in a research report on Friday, July 31st. Wells Fargo & Company raised their price target on Merit Medical Systems from $74.00 to $83.00 and gave the stock an “equal weight” rating in a research report on Friday, July 31st. Finally, Needham & Company LLC upped their price objective on shares of Merit Medical Systems from $90.00 to $101.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Eight investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, Merit Medical Systems has a consensus rating of “Moderate Buy” and a consensus price target of $100.00.

Merit Medical Systems Stock Performance

Shares of NASDAQ:MMSI opened at $90.28 on Tuesday. Merit Medical Systems, Inc. has a 1 year low of $59.74 and a 1 year high of $94.75. The stock has a market capitalization of $5.39 billion, a price-to-earnings ratio of 37.31, a price-to-earnings-growth ratio of 2.28 and a beta of 0.48. The company has a debt-to-equity ratio of 0.44, a current ratio of 4.20 and a quick ratio of 2.79. The company’s 50 day simple moving average is $77.88 and its 200 day simple moving average is $72.58.

Merit Medical Systems (NASDAQ:MMSI) last released its earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share for the quarter, topping the consensus estimate of $0.96 by $0.23. The firm had revenue of $418.84 million during the quarter, compared to analysts’ expectations of $405.25 million. Merit Medical Systems had a return on equity of 13.75% and a net margin of 9.22%.The company’s quarterly revenue was up 9.5% on a year-over-year basis. During the same period in the prior year, the company earned $1.01 earnings per share. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. As a group, research analysts predict that Merit Medical Systems, Inc. will post 3.81 EPS for the current fiscal year.

Merit Medical Systems Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.